Oragenics, Inc.

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026 Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical development Forum convenes leading pharmaceutical scientists, device developers, and regulators focused on nasal drug delivery SARASOTA, Fla.

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status.

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) traded up 0.2% on Tuesday. The stock traded as high as $0.5490 and last traded at $0.5489. 31,024 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 24,280 shares. The stock had previously closed at $0.5480. Oragenics Trading

Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital — are now active and enrolling, following Royal Adelaide Hospital's Research Governance Office (RGO) approval Alfred Health enrolls first participant in the Phase IIa clinical trial Company submits Type B meeting request to the U.S. Food and Drug Administration (FDA), advancing the U.S. regulatory pathway for ONP-002 SARASOTA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that all three sites in its Australian Phase IIa clinical trial are now active and enrolling — alongside continued progress on its U.S. regulatory program for ONP-002, being evaluated for the treatment of mTBI (concussion).